Aclinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: A case report

Chiara De Divitiis, Claudia Von Arx, Roberto Carbone, Fabiana Tatangelo, Elena Di Girolamo, Giovanni Maria Romano, Alessandro Ottaiano, Elisabetta De Lutio Di Castelguidone, Rosario Vincenzo Iaffaioli, Salvatore Tafuto

Research output: Contribution to journalArticlepeer-review

Abstract

Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.

Original languageEnglish
Pages (from-to)669-675
Number of pages7
JournalOncoTargets and Therapy
Volume8
DOIs
Publication statusPublished - Mar 31 2015

Keywords

  • Metastatic tumor of the ileum
  • Neuroendocrine tumor
  • Octreotide
  • Radiological tumor response
  • Somatostatin analogs

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Aclinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: A case report'. Together they form a unique fingerprint.

Cite this